NPM1 and acute myeloid leukemia: Previous studies showed a superior 2-year OS for NPM1-mutated AML patients achieving (bone marrow) MRD negativity in the first four VEN/HMA cycles, demonstrating a strong prognostic value of MRD diagnostics in patients treated with VEN/HMA [20].